Alpro Group, Malaysia’s largest prescription pharmacy chain, has signed a Memorandum of Understanding with AGTC Genomics to enhance healthcare in Malaysia through Pharmacogenomics (PGx) and Nutrigenomics (NGx) services. This collaboration aims to reduce medication errors and adverse drug reactions (ADRs), which affect 1 in 10 hospitalised patients in Malaysia, with over 30% of these incidents being preventable.

The partnership will integrate PGx and NGx into everyday healthcare, combining Alpro’s network of pharmacies and clinics with AGTC’s advanced genetic testing. PGx focuses on personalising medication based on a patient’s genetic profile, ensuring safer and more effective prescriptions. NGx will offer insights into optimal dietary choices based on genetics to support overall health.

Prof Leong Chee Onn, CEO of AGTC Genomics, emphasised the importance of providing the right medication at the right dose, stating, “We are bringing the power of genetic insights to communities across Malaysia, advancing safer and more effective healthcare solutions.”

Dr Ng Ming Lee, Medical Director of Alpro Clinic, noted that the collaboration aligns with Alpro Group’s commitment to improving healthcare quality nationwide, aiming to reduce medication errors and elevate the standard of care for Malaysians.

The partnership will also include educational initiatives to raise awareness about genetic testing, with the goal of empowering Malaysians to make informed health decisions. Services will be available at Alpro Pharmacies across Malaysia, offering genetic testing to help individuals access personalised medication.